


Análisis masivos de datos y reutilización de datos para la investigación biomédica: experiencias concretas



Ferran Sanz

La Plataforma Tecnológica Española Medicamentos Innovadores cuenta con apoyo del Ministerio de Economía, Industria y Competitividad

Biomedical Big Data






Ejemplos de proyectos de *Big Data*

2017

MEDICAMENTOS INNOVADORES
Plataforma Tecnológica Española



Ejemplos de proyectos IMI relacionados con el *Big Data*:

- **EMIF:** Plataforma para la (re)utilización de datos clínicos en la investigación biomédica.
- **Open PHACTS:** Descubrimiento de conocimiento en el I+D farmacéutico mediante la aplicación de la tecnología de la web semántica.
- **eTOX:** Predicción de la toxicidad de medicamentos mediante análisis integrado de casuística acumulada en la industria farmacéutica (continuidad y extensión a través de **eTRANSAFE**)

Otros proyectos europeos (H2020) sobre el tema:

- **EU-ADR:** Detección de efectos adversos mediante análisis masivo de historias clínicas y sustanciación bioinformática.
- **MedBioinformatics:** Aplicaciones bioinformáticas para la investigación translacional y la práctica clínica.
- **ELIXIR-EXCELERATE:** Infraestructura Europea de datos en ciencias de la vida.

Why EMIF is Needed

Potential Applications for Real World Data in Drug Development

Discovery



- Biomarker discovery
- Predictive modeling
- Disease insight generation (opportunity identification)

Development



- Trial design and feasibility analysis
- Electronic health record (EHR)-facilitated recruitment
- Prospective cohort selection

Launch / Post-launch



- Analysis treatment pathways
- Collection of clinical and economic evidence
- Ongoing efficiency and safety monitoring

Why EMIF is Needed

Potential Applications for Real World Data in Drug Development

Discovery

Development

Launch / Post-launch

InSite Platform (real world data driven clinical trial design and execution)
<http://es.slideshare.net/PatrickBasanez/info-sheet-champion-programme>

- Biomarker discovery
- Predictive modeling
- Disease insight generation (opportunity identification)

- Trial design and feasibility analysis
- Electronic health record (EHR)-facilitated recruitment
- Prospective cohort selection

- Analysis treatment pathways
- Collection of clinical and economic evidence
- Ongoing efficiency and safety monitoring

Why EMIF is Needed

Potential Applications for Real World Data in Drug Development

Discovery



- Biomarker discovery
- Predictive modeling
- Disease insight generation (opportunity identification)

Development




- Trial design and feasibility analysis
- Electronic health record (EHR)-facilitated recruitment
- Prospective cohort selection

Launch / Post-launch



- Analysis treatment pathways
- Collection of economic evidence
- Ongoing efficiency and safety monitoring

eu-adr ↪



Drug-Induced Acute Myocardial Infarction: Identifying 'Prime Suspects' from Electronic Healthcare Records-Based Surveillance System


Preciosa M. Coloma^{1*}, Martijn J. Schuemie¹, Gianluca Trifirò^{1,2}, Laura Furlong³, Erik van Mulligen¹, Anna Bauer-Mehren³, Paul Avillach^{4,5}, Jan Kors¹, Ferran Sanz³, Jordi Mestres³, José Luis Oliveira⁶, Scott Boyer⁷, Ernst Ahlberg Helgee⁷, Mariam Molokhia⁸, Justin Matthews⁹, David Prieto-Merino⁹, Rosa Gini¹⁰, Ron Herings¹¹, Giampiero Mazzaglia¹², Gino Picelli¹³, Lorenza Scotti¹⁴, Lars Pedersen¹⁵, Johan van der Lei¹, Miriam Sturkenboom^{1,16}, on behalf of the EU-ADR consortium


Automatic Filtering and Substantiation of Drug Safety Signals

Anna Bauer-Mehren¹, Erik M. van Mullingen², Paul Avillach^{3,4}, María del Carmen Carrascosa¹, Ricard Garcia-Serna¹, Janet Piñero¹, Bharat Singh², Pedro Lopes⁵, José L. Oliveira⁵, Gayo Diallo³, Ernst Ahlberg Helgee⁶, Scott Boyer⁶, Jordi Mestres¹, Ferran Sanz¹, Jan A. Kors², Laura I. Furlong^{1*}

1 Research Programme on Biomedical Informatics (GRIB), IMIM-Hospital del Mar Research Institute, DCEX, Universitat Pompeu Fabra, Barcelona, Spain, **2** Erasmus University Medical Center, Rotterdam, The Netherlands, **3** LESIM-ISPED, Université de Bordeaux, Bordeaux, France, **4** LERTIM, EA 3283, Faculté de Médecine, Université de Aix-Marseille, Marseille, France, **5** DETI/IEETA, Universidade de Aveiro, Aveiro, Portugal, **6** AstraZeneca, Mölndal, Sweden







We report a Japanese adult form of CPT II deficiency associated with a homozygous F383Y mutation causing myalgia and rhabdomyolysis.

A novel variant of CPT II was found in a patient with rhabdomyolysis & acute renal failure: a deletion of cytosine & thymine at codon 408, resulting in a stop signal at 420, & an Arg631Cys mutation/frame shift at 408 has never been described before.


From Bauer-Mehren A, Bundschus M, Rautschka M, Mayer MA, Sanz F, Furlong LI. PLoS One 2011; 6(6): e20284

- Un recurso integral de información sobre las asociaciones entre genes y enfermedades humanas.
- Integra información de bases de datos disponibles públicamente y de la literatura científica mediante la minería de textos.
- DisGeNET v4.0 (Junio 2016) contiene 429.036 asociaciones que involucran 17.381 genes y 15,093 enfermedades y fenotipos
- Disponible libremente en: <http://www.disgenet.org>





DisGeNET version 4.0: Top scoring genes for Major Depression

Gene	Number of diseases	DisGeNET score	DSI	DPI	Number of PMIDs	Number of SNPs
SLC6A4	374	0.236	0.411	0.852	157	5
TPH2	89	0.211	0.548	0.667	26	1
HTR2A	222	0.155	0.463	0.778	45	17
PCLO	20	0.130	0.696	0.333	12	5
CRHR1	118	0.127	0.531	0.778	11	11
CYP2D6	316	0.127	0.428	0.852	11	2
FKBP5	78	0.126	0.563	0.814	16	1
SP4	16	0.125	0.739	0.296	3	1
GRM7	32	0.123	0.666	0.444	5	1
GNAI3	7	0.122	0.812	0.296	2	1






Which schizophrenia genes are targeted by chemicals?



DisGeNET in
Linked Open Data



¡Muchas gracias por su atención!

<http://grib.upf.edu>

